- Cell Biology
- Product Type
- Research Area
- New Products
- About Tocris
- Contact Us
Lactate Dehydrogenase A (LDHA; LDH5), EC 22.214.171.124, is one of five isoforms of the lactate dehydrogenase family. It catalyzes the conversion of pyruvate to lactate under anaerobic conditions and is key in the altered glycolytic metabolism that is a feature of cancer cells.
|Cat No||Product Name / Activity|
|Lactate dehydrogenase inhibitor; impairs aerobic glycolysis|
|Potent, selective LDHA inhibitor|
Lactate Dehydrogenase A (LDHA; LDH5), EC 126.96.36.199, is one of five isoforms of the lactate dehydrogenase family. It catalyzes the conversion of pyruvate to lactate under anaerobic conditions and plays a key role in the altered glycolytic metabolism that is a feature of cancer cells. LDHs are tetrameric enzymes comprising two different types of subunit, M and H; different combinations of these subunits result in five separate isoforms. LDHA, which is found mainly in skeletal muscle but also in tumors, consists of four M subunits.
LDHA is overexpressed in a wide range of tumors and is associated with the more aggressive cancer phenotypes and poor prognosis. Expression of LDHA is regulated by hypoxia inducible factor-1 (HIF-1) and the oncogene c-Myc. The enzyme is necessary for tumor maintenance, since cancer cells rely on glycolytic metabolism for energy, whereas it is not essential for normal healthy cells that rely on oxidative phosphorylation. Inhibition of LDHA has been shown in animal models to reduce tumor growth, increase oxidative stress and induce apoptosis. The enzyme is therefore being evaluated as a therapeutic target in cancer metabolism.